Mike Hollan is an assistant managing editor for Pharmaceutical Executive and Medical Device and Technology and can be reached at mhollan@mjhlifesciences.com.
As new forms of cell and gene therapies continue to be developed, life sciences companies and payers need to find alternative ways to pay for these expensive treatments. Value-based contracts, though slow to gain traction so far, may provide the solution these groups are looking for.
Pharma companies are teaming with academic institutions earlier in the R&D process.
Kimberly Moran, head of rare diseases in the US for UCB, started off working in medicine but quickly learned the importance of the business side of industry—and its role in helping improve the diagnosis and access paths for underserved patient segments.
Companies should search within to gain talent edge.
Senior leaders focused on the advancement of digital medicine and health meet to discuss the importance of these tools for life sciences companies, payers, and others in harnessing a healthcare future that will be increasingly dominated by holistic treatment and delivery.
AI drives new signal-detection efforts in Alzheimer’s and ALS.
Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.
Launch of novel drug for rare neuromuscular disorder seeks to give voice to the patients.
How companies can adapt to today’s fast-changing hiring climate.
How one company in particular has adjusted its internal and customer-facing strategies in compliance training amid today’s heightened business-risk climate.
The road to precision medicine as a fixture in healthcare delivery is still a journey, but recent advances and new understandings in gene profiling, biomarker development, and AI and data analytics are steadily bringing these therapies closer to the individual patient every day.
The technology is not just about digital enablement anymore.
COVID-19 pandemic, the challenging capital-markets climate in biotech, and a more innovative and specialty treatment focus has increased reliance on the finance arm as a key strategic cog.
While patients continue to benefit from increased product launches, the pandemic is still having an impact on caseload.